Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • TA343
  • Published: 

History

Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line) [ID650]: equality impact assessment - guidance development

Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line) [ID650]: final appraisal determination

Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line) [ID650]: appraisal consultation 2

Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line) [ID650]: appraisal consultation

Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line): equality impact assessment - scoping

Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line): response to consultee and commentator comments on the draft scope and provisional matrix

Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line): final scope

Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line): final matrix

Leukaemia - obinutuzumab: appendix B - draft scope for consultation (pre-referral) - August 2013

Leukaemia - obinutuzumab: appendix C - provisional matrix (pre-referral) - August 2013